{"id":"W2979372680","doi":"10.1182/blood.v124.21.1701.1701","title":"Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Follicular lymphoma; Tolerability; Chronic lymphocytic leukemia; Bendamustine; Phases of clinical research; Lymphoma; Gastroenterology; Clinical endpoint; Progressive disease; Oncology; Adverse effect; Chemotherapy; Clinical trial; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001186891,0.001090621,0.001333341,0.0004180649,0.0004216585,0.001013841,0.0006912042,0.0009244697,0.004797878],"category_scores_gemma":[0.0005954223,0.0004417457,0.0009327004,0.0003956759,0.0004741749,0.0005455293,0.0003400563,0.002483439,0.001185066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001050052,"about_ca_system_score_gemma":0.001545795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008101117,"about_ca_topic_score_gemma":0.002969023,"domain_scores_codex":[0.9996829,0.0001279049,0.00001775365,0.00006272175,0.00004113848,0.00006761921],"domain_scores_gemma":[0.9995885,0.00004720145,0.00006339782,0.00003401989,0.00004111255,0.0002256806],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4958936,0.1069373,0.02486828,0.001984205,0.002593923,0.00156946,0.0006073256,0.004188458,0.1359572,0.0007561059,0.01780101,0.2068431],"study_design_scores_gemma":[0.5164892,0.4201013,0.03523729,0.0001059672,0.000978885,0.001566266,0.0001132826,0.002495167,0.008674319,0.000593321,0.01358553,0.00005948479],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792795,0.00408723,0.001592384,0.000813398,0.00009363742,0.006108312,0.003121605,0.0002231408,0.004680762],"genre_scores_gemma":[0.9764913,0.002137468,0.003539695,0.001963048,0.0001649666,0.005187762,0.005852837,0.00004932916,0.004613625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004797878,"threshold_uncertainty_score":0.01605052,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01314186849954683,"score_gpt":0.2788585589699332,"score_spread":0.2657166904703863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}